Beutel Goodman & Co Ltd. Sells 715 Shares of Smith & Nephew plc (NYSE:SNN)

Beutel Goodman & Co Ltd. decreased its position in shares of Smith & Nephew plc (NYSE:SNN) by 4.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,555 shares of the medical equipment provider’s stock after selling 715 shares during the quarter. Beutel Goodman & Co Ltd.’s holdings in Smith & Nephew were worth $382,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of SNN. Pathstone Holdings LLC boosted its holdings in Smith & Nephew by 14.8% in the third quarter. Pathstone Holdings LLC now owns 48,903 shares of the medical equipment provider’s stock valued at $1,523,000 after acquiring an additional 6,317 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Smith & Nephew by 29.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider’s stock valued at $847,000 after purchasing an additional 6,164 shares during the last quarter. Citigroup Inc. grew its position in shares of Smith & Nephew by 18.5% during the 3rd quarter. Citigroup Inc. now owns 119,215 shares of the medical equipment provider’s stock worth $3,712,000 after buying an additional 18,630 shares during the period. Cerity Partners LLC grew its position in shares of Smith & Nephew by 31.5% during the 3rd quarter. Cerity Partners LLC now owns 19,001 shares of the medical equipment provider’s stock worth $592,000 after buying an additional 4,552 shares during the period. Finally, Townsquare Capital LLC raised its stake in shares of Smith & Nephew by 5.4% during the third quarter. Townsquare Capital LLC now owns 14,759 shares of the medical equipment provider’s stock worth $460,000 after buying an additional 761 shares during the last quarter. 25.64% of the stock is currently owned by institutional investors.

Smith & Nephew Trading Down 1.4 %

SNN opened at $28.03 on Friday. The firm’s fifty day moving average is $27.13 and its two-hundred day moving average is $26.99. The firm has a market cap of $12.25 billion, a PE ratio of 12.97, a price-to-earnings-growth ratio of 1.26 and a beta of 0.83. Smith & Nephew plc has a twelve month low of $23.65 and a twelve month high of $31.72. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51.

Smith & Nephew Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Friday, March 28th will be paid a $0.447 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a yield of 2.5%. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. Smith & Nephew’s payout ratio is presently 41.20%.

Analysts Set New Price Targets

A number of research firms have commented on SNN. UBS Group lowered shares of Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Canaccord Genuity Group restated a “hold” rating and issued a $27.00 price target on shares of Smith & Nephew in a research report on Monday, March 17th. Finally, StockNews.com upgraded Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $27.00.

Smith & Nephew Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.